Skip to main content

Lumira Ventures — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

41
Companies
$1.3B
Total invested
$36.4M
Avg. check
13
Industries
Biotechnology 16Medical 12Health Care 11Therapeutics 9Medical Device 9Pharmaceutical 4+7 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 1–24 of 41
Damona Pharmaceuticals
September 2022

Damona Pharmaceuticals is a pre-clinical pharmaceutical company treats and prevents cognitive deficits.

Medical · Toronto$5.5M Seed
Thryv Therapeutics
September 2025

Thryv Therapeutics is a precision medicine approach to treat patients with Long QT Syndrome and potentially other arrhythmias.

Biotechnology · LavalVenture - Series Unknown
Spectrawave
September 2024

Spectrawave is a medical device company that develops optical diagnostic and therapeutic devices.

Biotechnology · Waltham$50.0M Series B
Aurinia Pharmaceuticals
June 2026

Aurinia develops and commercializes therapies to treat targeted patient populations suffering from serious auto-immune diseases.

Biopharma · Victoria$3.1M Post-IPO Equity
Cour Pharmaceuticals Development
June 2026

Cour Pharmaceuticals Development is developing nanoparticle technology to help reset the immune system of multiple sclerosis (MS) patients.

Biotechnology · Skokie$50.0M Series B
Notch Therapeutics
June 2024

Notch develops immune cell therapy developing a next-generation pipeline that is compatible and focuses on initial cancer cells.

Biotechnology · Toronto$15.5M Venture - Series Unknown
Edesa Biotech
June 2026

Edesa develops treatments for dermatological and anorectal diseases. Edesa merged with Stellar Biotechnologies in 2019.

Biotechnology · Markham$2.5M Post-IPO Equity
Nervonik
April 2026

Nervonik is a medical device company developing an opioid-free peripheral nerve stimulation (PNS) system.

Manufacturing · Los Angeles$52.5M Series B
Congruence Therapeutics
March 2026

Congruence Therapeutics operates as a biotechnology company.

Biotechnology · Montréal$39.5M Venture - Series Unknown
Specific Biologics
March 2026

Specific Biologics develops novel gene editing technologies to treat diseases at the genetic level in cells inside the body.

Biotechnology · Toronto$1.3M Grant
Corvia Medical
June 2025

Corvia Medical develops transcatheter device designed to reduce the symptoms or slow the progression of heart failure.

Biopharma · Andover$55.0M Venture - Series Unknown
Bardy Diagnostics
May 2025

Bardy Diagnostics is a developer of a cardiac monitor and arrhythmia detection device .

Health Care · Seattle$10.5M Venture - Series Unknown
Puzzle Medical Devices
April 2025

Canadian company specializing in the development of a minimally invasive long-term hemodynamic transcatheter pump.

Health Care · Montreal$30.3M Series A
Sound Blade Medical
January 2025

Sound Blade Medical is an early stage medical device startup which transforms healthcare by developing endoscopic, image-guided histotripsy.

Health Care · Halifax$16.5M Series A
XyloCor Therapeutics
January 2025

XyloCor Therapeutics is a biopharmaceutical company intended to develop gene therapy for people with coronary artery disease.

Biotechnology · King Of Prussia$67.5M Series B
KisoJi Biotechnology
December 2024

KisoJi Biotechnology is a biotechnology company focused on healthcare and life sciences for research and development industries.

Biotechnology · Laval-ouest$40.6M Series B
Endogenex
June 2024

Endogenex develops an endoscopic procedure to help patients with type 2 diabetes regain control of their blood glucose levels.

Health Care · Plymouth$88.0M Series C
Deka Biosciences
December 2023

Early stage biotechnology company

Biotechnology · Germantown$29.9M Venture - Series Unknown
OncoMyx Therapeutics
December 2021

OncoMyx Therapeutics develops oncolytic immunotherapies to assist in creating an immune response and treat cancer.

Biotechnology · Phoenix$50.0M Series B
AmacaThera
December 2023

AmacaThera's injectable hydrogel platform provides localized, sustained drug delivery to improve patient outcomes.

Biopharma · Toronto$50K Grant
Cyrano Therapeutics
January 2024

Cyrano Therapeutics is developing an intranasal product designed to restore function in patients with a chronic loss of taste and smell.

Health Care · Washington$9.0M Series B
Antios Therapeutics
November 2021

Antios Therapeutics is a biopharmaceutical company developing innovative therapies for viral diseases.

Biopharma · Atlanta$75.0M Series B
Medexus Pharma
November 2025

Medexus Pharma is a rare disease pharmaceutical company focusing on therapeutic areas of rheumatology and auto-immune conditions.

Biotechnology · Chicago$26.0M Post-IPO Debt
Axonis Therapeutics
October 2024

Axonis Therapeutics is a neuro-focused biotechnology company that focuses on the development of novel neuromedicines.

Biotechnology · Boston$115.0M Series A

Where Lumira Ventures invests

Biotechnology16
Medical12
Health Care11
Therapeutics9
Medical Device9
Pharmaceutical4

About Lumira Ventures's portfolio

How many companies has Lumira Ventures invested in?▸

Lumira Ventures has invested in 41 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Lumira Ventures invest in?▸

Lumira Ventures's top investment sectors include Biotechnology, Medical, Health Care, Therapeutics, Medical Device. The firm invests across 13 different industry categories.

What is Lumira Ventures's largest investment?▸

Among tracked funding rounds, Axonis Therapeutics received $115.0M in a Series A round. Lumira Ventures's total known invested capital is $1.3B.

What is the average investment size for Lumira Ventures?▸

Lumira Ventures's average investment size is $36.4M across its portfolio of 41 companies.

What are Lumira Ventures's most recent investments?▸

Recent Lumira Ventures portfolio additions include Damona Pharmaceuticals, Thryv Therapeutics, Spectrawave, Aurinia Pharmaceuticals, Cour Pharmaceuticals Development. These companies were founded in 2020 or later.

Reach the founders behind these 41 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →